Ftse Mib
36.191,17
-0,03%
DAX
21.282,18
-0,48%
S&P 500
6.012,28
-1,46%
NASDAQ
19.341,83
-3,07%
Bitcoin
101.420,61
-0,64%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Longeveron Inc (LGVNR) Longeveron Inc (LGVNR) Notizie

Longeveron Inc

LGVNR
0,0005
0,00 (0,00%)
27 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Diritto
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/12/202415:10GLOBELongeveron to Present at Biotech Showcase 2025
12/11/202422:05GLOBELongeveron® Announces Third Quarter 2024 Financial Results..
11/11/202415:05GLOBELongeveron® Appoints Devin Blass as Chief Technology Officer..
04/11/202422:05GLOBELongeveron® to Report Third Quarter 2024 Financial Results..
29/10/202415:00GLOBELongeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease..
27/10/202420:10GLOBELongeveron® Presents Lomecel-B™ Long-term Transplant-free..
14/10/202415:05GLOBELongeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected..
09/10/202415:05GLOBELongeveron® Lomecel-B™ 5-Year Long-term Transplant-free..
07/10/202415:05GLOBELongeveron® to Present at the UBS Virtual Organ Restoration..
02/10/202415:05GLOBELongeveron® to Participate in the 3rd Annual ROTH Healthcare..
26/9/202415:05GLOBELongeveron to Attend Alliance for Regenerative Medicine’s..
03/9/202415:00GLOBELongeveron® Announces Positive Type C Meeting with U.S. FDA..
26/8/202422:05GLOBELongeveron to Present at the H.C. Wainwright 26th Annual..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:15EDGAR2Form 8-K - Current report
14/8/202422:05GLOBELongeveron® Announces Second Quarter 2024 Financial Results..
13/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12/8/202422:36EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/8/202400:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/8/202400:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/8/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/8/202422:42EDGAR2Form S-1 - General form for registration of securities under..
05/8/202422:05GLOBELongeveron® to Report Second Quarter 2024 Financial Results..
28/7/202422:51GLOBELongeveron® Presents Study Results from CLEAR MIND Phase 2a..
19/7/202422:05GLOBELongeveron Announces Closing of $9.0 Million Registered..
19/7/202414:30EDGAR2Form 8-K - Current report
19/7/202414:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/7/202414:45GLOBELongeveron Announces $9.0 Million Registered Direct Offering..
17/7/202414:30EDGAR2Form 8-K - Current report
17/7/202414:00GLOBELongeveron® Announces U.S. FDA Grants Fast Track Designation..
10/7/202422:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/7/202414:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/7/202414:00EDGAR2Form 8-K - Current report
10/7/202413:30GLOBELongeveron® Announces U.S. FDA Grants..
09/7/202415:00GLOBENeha Motwani Elected to Longeveron® Board of Directors
08/7/202415:00GLOBEGene Therapy Pioneer Roger Hajjar, MD, Elected to..
03/7/202422:15EDGAR2Form 8-K - Current report
28/6/202422:16EDGAR2Form S-1 - General form for registration of securities under..
18/6/202422:48GLOBELongeveron Raises $4.4 Million in Gross Proceeds from..
18/6/202422:30EDGAR2Form 8-K - Current report
17/6/202415:00GLOBELongeveron® to Present at the Virtual Life Sciences Investor..
17/6/202414:38GLOBELongeveron Announces Exercise of Warrants for $4.4 Million..
11/6/202415:00GLOBELongeveron® Announces Completion of Successful Investigator..
Apertura: Min: Max:
Chiusura: 0,0005

La tua Cronologia

NASDAQ
LGVNR
Longeveron
BOV
A2RR34
Arrowhead Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network